Peptides Binding AlphaVbeta3 Integrin for Anxiety and Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for psychiatric illnesses and cancer related to serotonin transport and αvβ3 activity are limited in efficacy, particularly in addressing anxiety, tumor growth, and metastasis.
Innovation Solution
Development of specific peptides that bind to the αvβ3 integrin, such as those with sequences like NLSSSWI, PPSNHLL, APSPSRL, SSAGSLF, and PLHARLP, which are administered to modulate serotonin transport and inhibit cancer cell proliferation and metastasis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for psychiatric illnesses and cancer are used, then existing therapeutic approaches are maintained, but efficacy is limited in addressing anxiety, tumor growth, and metastasis
Solution Approach 1:
The peptide compositions are designed to bind to αvβ3 integrin which is involved in multiple pathological processes including cancer metastasis, angiogenesis, and serotonin transport regulation. This single therapeutic agent can therefore address multiple conditions (cancer, psychiatric disorders) through its ability to modulate the same molecular target's different functions, achieving multi-functionality and improved versatility across different disease states
2Measurement precision
If specific peptides binding to αvβ3 integrin are developed, then selective binding capability is achieved, but complexity of therapeutic development increases
Solution Approach 1:
The invention extracts and utilizes the specific amino acid sequence motif (NLSSSWI, PPSNHLL, APSPSRL, SSAGSLF, or PLHARLP) that confers αvβ3 integrin binding capability. By identifying and isolating this critical binding motif from complex protein structures, the invention achieves high binding specificity while simplifying the overall therapeutic design to focused peptide sequences rather than requiring complex molecular structures
Solution Approach 2:
The invention achieves selective binding by optimizing specific parameters of the peptide sequences including amino acid composition, sequence length (7-50 residues), and cyclic structure formation through disulfide bonds. These parameter optimizations enable high affinity and specificity for αvβ3 integrin while maintaining manageable complexity in peptide design and synthesis
3Reliability
If peptide treatments are administered for cancer and psychiatric disorders, then therapeutic effects are achieved, but need for effective treatments across multiple disease types is addressed
Solution Approach 1:
The peptide compositions serve as a universal therapeutic platform that can treat both cancer and psychiatric disorders by targeting the common molecular mechanism of αvβ3 integrin. The same peptide sequences demonstrate efficacy in inhibiting cancer cell proliferation and metastasis while also modulating serotonin transport in psychiatric conditions, providing a versatile treatment approach across diverse disease types
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptides effectively reduce anxiety, inhibit cancer cell growth, and prolong survival in melanoma-bearing mice by selectively binding to αvβ3 integrin, demonstrating therapeutic potential for both psychiatric disorders and cancer treatment.
Implementation Method 1
specific peptides that bind to the αvβ3 integrin
Data Source
AI summary
Isolated peptides are disclosed. The peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-5 and 11-15, with the proviso that the amino acid sequence does not consist of SEQ ID NO: 11, SEQ ID NO: 15 or SEQ ID NO: 1, wherein the peptide is no longer than 50 amino acids. Pharmaceutical compositions comprising same and uses thereof for treatment of diseases associated with serotonin transport and/or αVβ3 activity are also disclosed.